Hikma Pharmaceuticals PLC
Open
BrancheGesundheitswesen
1,530 0.92
Übersicht
Veränderung der Aktienkurses
24h
Min
1515
Max
1536
Einkommen | 165M |
|---|---|
Verkäufe | 41M 1.7B |
KGV Branchendurchschnitt | 10.891 50.958 |
EPS | 1.07 |
Dividendenrendite | 5.65 |
Gewinnspanne | 9.698 |
Angestellte | 9,400 |
EBITDA | 152M 411M |
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +14.11% upside |
Dividendenrendite Branchendurchschnitt | 5.65% 2.41% |
|---|---|
Nächstes Ergebnis | 6. Aug. 2026 |
Nächste Dividendenausschüttung | 17. Sept. 2026 |
Nächstes Ex-Dividendendatum | 13. Aug. 2026 |
Marktkapitalisierung | -476M 3.2B |
|---|---|
Vorheriger Eröffnungskurs | 1529.08 |
Vorheriger Schlusskurs | 1530 |
Nachrichtenstimmung
By Acuity
17%
83%
28 / 342 Ranking in Healthcare
Hikma Pharmaceuticals PLC Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.